Advertisement
Mergers and Acquisitions
Subscribe to Mergers and Acquisitions

The Lead

Hedge Fund Third Point Urges Amgen to Consider Breakup

October 22, 2014 8:24 am | by The Associated Press | News | Comments

A hedge fund run by a famed investor has taken a large stake in Amgen and now wants the biotech drugmaker to consider splitting up into two. In a letter to investors, Third Point, a hedge fund run by Daniel Loeb, said it has recently increased its stake by an unspecified amount, making it one of the drugmaker's top shareholders.

AbbVie to Pay Shire $1.64B Fee Over Canceled Merger

October 21, 2014 8:13 am | News | Comments

AbbVie is walking away from its proposed $55 billion takeover bid of Shire and has agreed to pay...

Valeant Considering Higher Bid for Allergan after Reporting Strong Q3 Results

October 20, 2014 1:26 pm | by Ross Marowits, The Canadian Press | News | Comments

Valeant Pharmaceuticals said that its strong third-quarter results and a higher growth forecast...

BioProcess Technology Consultants Acquires CTD Quality Consulting

October 20, 2014 9:37 am | News | Comments

CTD Quality Consulting, founded in 2004, specializes in regulatory submissions, regulatory...

View Sample

FREE Email Newsletter

Nuvo Research Sells PENNSAID U.S. Rights to Horizon Pharma

October 17, 2014 8:01 am | News | Comments

Nuvo Research Inc. has completed the sale of its PENNSAID 2% U.S. sales and marketing rights to Horizon Pharma for a cash payment of US$45 million (CDN$50 million) which was payable on closing.          

AbbVie Wants Out of $55B Shire Deal

October 16, 2014 8:11 am | by The Associated Press | News | Comments

AbbVie's board is telling shareholders to vote against its own $55 billion takeover bid for the Irish drugmaker Shire after the U.S. made reincorporating overseas a less lucrative tax maneuver.          

Shire: AbbVie Should Proceed with $55B Acquisition

October 15, 2014 8:06 am | by The Associated Press | News | Comments

Shire wants AbbVie to stick with its roughly $55 billion acquisition bid, and it is reminding its U.S. counterpart of the hefty breakup fee it will receive if things don't work out.            

Advertisement

Endo Buys Struggling Auxilium for $2.6B to Augment Urology Franchise

October 10, 2014 9:36 am | News | Comments

Endo International’s $2.6 billion purchase of Auxilium Pharmaceuticals complements Endo’s urology and male health portfolio, and the company intends to leverage its resources to optimize and drive increased adoption of three key Auxilium drugs, according to an analyst with research and consulting firm GlobalData.

Impax to Acquire Tower Holdings and Lineage Therapeutics for $700M

October 9, 2014 8:20 am | News | Comments

Impax Laboratories today announced the execution of a definitive agreement under which Impax will acquire Tower Holdings, Inc., including operating subsidiaries CorePharma LLC and Amedra Pharmaceuticals LLC, and Lineage Therapeutics Inc. for $700 million in cash.

Endo to Buy Auxilium in Deal Worth $2.6B

October 9, 2014 7:46 am | by The Associated Press | News | Comments

Ireland's Endo International is buying Auxilium Pharmaceuticals Inc. in a sweetened cash-and-stock deal valued at $2.6 billion a few weeks after Auxilium rejected a lower bid for the company. Endo says it will pay $33.25 in cash and stock for each Auxilium share.

Actavis to Acquire Durata Therapeutics

October 6, 2014 8:16 am | News | Comments

Actavis has entered into a definitive merger agreement under which a subsidiary of Actavis will commence a tender offer to acquire all of the outstanding shares of Durata common stock for $23.00 per share in cash, or approximately $675 million. 

Overseas Deal Rules End One Combo, Alter Another

October 3, 2014 1:46 pm | by Tom Murphy - AP Business Writer - Associated Press | News | Comments

New government rules aimed at curbing overseas deals that cut corporate taxes appear to be working, just not entirely the way regulators intended.                  

Advertisement

Salix Pharma Scraps Cosmo Technologies Merger

October 3, 2014 7:46 am | by The Associated Press | News | Comments

Salix Pharmaceuticals is scrapping its merger with the subsidiary of an Italian drugmaker after the U.S. created new limitations on the tax benefits of incorporating overseas.             

Pressure Mounting on Allergan as Proxy Firm ISS Criticizes Board Approach

October 2, 2014 3:52 pm | by Ross Marowits, The Canadian Press | News | Comments

Proxy advisory firm Institutional Shareholder Services has joined several large Allergan shareholders calling for a vote after reports surfaced that it is in talks to buy Salix Pharmaceuticals. The US$10 billion all-cash deal could make it too expensive for Valeant to purchase the company.

Catalent Acquires Redwood Bioscience and the SMARTag Technology Platform

October 2, 2014 10:42 am | News | Comments

Catalent Pharma Solutions has acquired the remaining stake in Redwood Bioscience Inc., and the SMARTag Antibody-Drug Conjugate (ADC) technology platform. The acquisition follows the successful achievement of in vivo and in vitro proof of concept milestones, recent compelling in vivo toxicology data, and strong customer interest in the SMARTag technology.

Sagent Pharmaceuticals Acquires Omega Laboratories

October 1, 2014 4:24 pm | News | Comments

Sagent Pharmaceuticals has acquired Omega Laboratories Limited, a specialty pharmaceutical company based in Montreal, Canada. Sagent acquired Omega for approximately US$85.3 million (C$95 million) in an all-cash deal.      

Merck Completes Sale of Consumer Unit to Bayer

October 1, 2014 3:15 pm | News | Comments

Merck has completed the sale of its consumer care business, which makes products including Claritin allergy medication and Coppertone sun-care line, to German health care company Bayer for $14.2 billion.        

Advertisement

WuXi PharmaTech Laboratory Testing Division Acquires XenoBiotic Laboratories

October 1, 2014 8:12 am | News | Comments

WuXi PharmaTech has acquired XenoBiotic Laboratories, Inc., a contract research organization with 27 years of successful operation that provides bioanalytical, drug metabolism, and pharmacokinetic services to the pharmaceutical, animal health, and agrochemical industries.

Johnson & Johnson Buying Alios for $1.75B

September 30, 2014 9:48 am | by The Associated Press | News | Comments

Johnson & Johnson is buying the biopharmaceutical company Alios BioPharma Inc. for about $1.75 billion. Alios is a privately held company that focuses on developing therapies for viral diseases. The deal includes Alios' portfolio of potential therapeutics for viral infections.

Daiichi Sankyo to Acquire Ambit Biosciences

September 29, 2014 10:15 am | News | Comments

Daiichi Sankyo Company and Ambit Biosciences, jointly announced today that they have entered into a definitive merger agreement under which Daiichi Sankyo will acquire all of the outstanding common stock of Ambit Biosciences for $15 per share in cash through a tender offer followed by a merger with a subsidiary of Daiichi Sankyo, or approximately $315 million on a fully diluted basis.

Chiltern Acquires Pacific Clinical Research

September 29, 2014 10:10 am | News | Comments

Chiltern has acquired Pacific Clinical Research, a pan-Asian CRO based in Singapore. The move allows Chiltern to offer integrated services throughout the Asia-Pacific region and strengthens in particular Chiltern's oncology and anti-infective offerings.

Amag Pharma to Spend $675M on Lumara Health

September 29, 2014 10:03 am | News | Comments

The Waltham, Massachusetts, company said Monday it will spend $600 million in cash and another $75 million in stock on the privately held Lumara, which makes Makena, a treatment designed to reduce the risk of premature birth.     

M&A Update: Abbott, CFR, Pfizer, InnoPharma

September 26, 2014 11:07 am | News | Comments

Pfizer announced that it has completed its acquisition of pharmaceutical development company, InnoPharma, Inc., and Abbott has acquired control of CFR Pharmaceuticals, more than doubling its Latin American-branded generics pharmaceutical presence.

Acorda Therapeutics to Acquire Civitas Therapeutics

September 24, 2014 8:05 am | News | Comments

Acorda Therapeutics has entered into an agreement to acquire Civitas Therapeutics, a privately-held biopharmaceutical company, for $525 million in cash. Acorda will obtain worldwide rights to CVT-301, a Phase 3 treatment candidate for OFF episodes of Parkinson’s disease (PD).

Pershing Capital Threatens to Sue Allergan if it Acquires Salix Without Vote

September 23, 2014 2:40 pm | by Ross Marowits, The Canadian Press | News | Comments

Allergan's largest shareholder, Pershing Square Capital, has threatened to sue the Botox maker if it attempts to buy Salix Pharmaceuticals without holding a shareholder vote. The investment fund headed by Bill Ackman has teamed up with Valeant Pharmaceuticals to make a $50-billion hostile takeover bid for Allergan.

Auxilium Pharma Rejects Endo's Takeover Offer

September 22, 2014 8:02 am | News | Comments

Auxilium, based in Chesterbrook, Pennsylvania, had adopted a one-year "poison pill" shareholder rights plan last week. The drugmaker continues to support its plan to combine with Canadian eye drugmaker QLT Inc. in an all-stock deal.    

Merck KGaA to Buy Sigma Aldrich for $17B

September 22, 2014 7:44 am | by David Mchugh - AP Business Writer - Associated Press | News | Comments

Merck says it has agreed to buy St. Louis-based chemical firm Sigma-Aldrich Corp. for $17 billion. Darmstadt-based Merck KGaA said Monday it is paying $140 per share in cash for all of Sigma-Aldrich's shares — a premium of 37 percent over Friday's closing price of $102.37.

PCI Acquires Biotec Services

September 19, 2014 8:21 am | News | Comments

The addition significantly expands PCI's presence in the UK/EU to support global investigational studies of medicinal products by adding packaging, storage and distribution capacity, as well as consultative services for clinical trial supplies. 

Auxilium Pharma Board Adopts Anti-Takeover Plan

September 17, 2014 8:48 am | by The Associated Press | News | Comments

The board of Auxilium Pharmaceuticals has adopted a "poison pill" shareholder rights plan to ward off a hostile takeover after Endo International PLC announced an unsolicited offer worth about $1.41 billion for its fellow drugmaker.   

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading